Schedule a Vaccination | How We're Keeping You Safe | What Patients & Families Need to Know
Director, Division of Oncology
Institute Co-Executive Director, Cancer and Blood Diseases Institute
Deb Kleisinger Endowed Chair
Professor, UC Department of Pediatrics
John P. Perentesis, MD, FAAP, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs and discovered genes important in the growth of normal and malignant cells. His laboratory is also using tumor patients genomics research for personalizing therapies. In national efforts for new anticancer drug development, he serves in key roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest children's cancer research entity.
In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national COG Executive Committee. He also serves as vice-chair for the COG Adolescent & Young Adult Cancer Steering Committee and as a member of the Hematology/Oncology and Institutional Performance Monitoring Steering Committees.
Dr. Perentesis has been elected by his peers for inclusion in the Best Doctors in America List since 1998.
Young adult cancers; acute myeloid & lymphoid leukemia; Hodgkin lymphoma; new anticancer therapy development
Molecular etiology and pharmacogenetics of pediatric cancers; Down syndrome-associated leukemia; new anticancer drug development
Leukemia, Sarcoma, Cancer and Blood Diseases, Young Adult Cancer
Oncology, Cancer and Blood Diseases
John P. Perentesis, MD, FAAP11/19/2020
John P. Perentesis, MD, FAAP6/29/2019
By John Perentesis, MD8/6/2016
By John Perentesis, MD11/7/2014
MD: University of Michigan, Ann Arbor, MI, 1980.
Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.
Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.
Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.
Certification: Pediatrics, 1989; Hematology/Oncology, 1990.
Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
Anderson, CP; Matthay, KK; Perentesis, JP; Neglia, JP; Bailey, HH; Villablanca, JG; Groshen, S; Hasenauer, B; Maris, JM; Seeger, RC; et al.
Pediatric Blood and Cancer.
Whole brain proton irradiation in adult Sprague Dawley rats produces dose dependent and non-dependent cognitive, behavioral, and dopaminergic effects.
Williams, MT; Sugimoto, C; Regan, SL; Pitzer, EM; Fritz, AL; Mascia, AE; Sertorio, M; Vatner, RE; Perentesis, JP; Vorhees, CV.
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: A Neurofibromatosis Clinical Trials Consortium study.
Ullrich, NJ; Prabhu, SP; Reddy, AT; Fisher, MJ; Packer, R; Goldman, S; Robison, NJ; Gutmann, DH; Viskochil, DH; Allen, JC; et al.
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
Jones, LM; Melgar, K; Bolanos, L; Hueneman, K; Walker, MM; Jiang, J; Wilson, KM; Zhang, X; Shen, J; Jiang, F; et al.
Journal of Clinical Investigation.
An open invitation to join the Pediatric Proton/Photon Consortium Registry to standardize data collection in pediatric radiation oncology.
Lawell, MP; Indelicato, DJ; Paulino, AC; Hartsell, W; Laack, NN; Ermoian, RP; Perentesis, JP; Vatner, R; Perkins, S; Mangona, VS; et al.
British Journal of Radiology.
The signaling axis atypical protein kinase C lambda/iota-Satb2 mediates leukemic transformation of B-cell progenitors.
Nayak, RC; Hegde, S; Althoff, MJ; Wellendorf, AM; Mohmoud, F; Perentesis, J; Reina-Campos, M; Reynaud, D; Zheng, Y; Diaz-Meco, MT; et al.
Improved chemotherapy modeling with RAG-based immune deficient mice.
Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O'Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC.
Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; et al.
Science Translational Medicine.
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016).
Widemann, BC; Lu, Y; Reinke, D; Okuno, SH; Meyer, CF; Cote, GM; Chugh, R; Milhem, MM; Hirbe, AC; Kim, A; et al.
Cancer cell metabolism: Implications for x-ray and particle radiation therapy.
Sertorio, M; Perentesis, JP; Vatner, RE; Mascia, AE; Zheng, Y; Wells, SI.
International journal of particle therapy.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462
© 1999-2021 Cincinnati Children's Hospital Medical Center. All rights reserved.